Continuing its interest in gene therapy discovery programmes, Takeda has agreed to pay US$45 M upfront and committed up to US$3.6 B more to access Poseida Therapeutics’ genetic engineering platforms. These will be utilised for the research and development of up to eight non-viral gene therapies for the treatment of haemophilia A and other genetic diseases, in the hope that they will provide a safer alternative to the standard viral vectors. The deal is Takeda’s second gene therapy collaboration exceeding US$1 B in October and its third gene therapy deal since August 2021.